Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

The 7 major Chimeric Antigen Receptor (CAR) T-Cell Therapy markets reached a value of US$ 3,979.2 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 12,482.2 Million by 2035, ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

The newly released GMP transposase is anticipated to provide a more direct route to clinical application for treatments such as chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...